ORGANIGRAM GLOBAL INC.
- Tickers
- OGI
- Headquarters
- Not recorded
- SEC CIK
- 0001620737
- Website
- Not recorded
Closing prices
Latest close, 0.96
| Date | Close |
|---|---|
| 1.57 | |
| 1.53 | |
| 1.54 | |
| 1.48 | |
| 1.53 | |
| 1.65 | |
| 1.64 | |
| 1.61 | |
| 1.54 | |
| 1.51 | |
| 1.49 | |
| 1.55 | |
| 1.51 | |
| 1.46 | |
| 1.48 | |
| 1.56 | |
| 1.61 | |
| 1.61 | |
| 1.64 | |
| 1.57 | |
| 1.57 | |
| 1.68 | |
| 1.64 | |
| 1.65 | |
| 1.63 | |
| 1.63 | |
| 1.67 | |
| 1.64 | |
| 1.92 | |
| 1.80 | |
| 1.96 | |
| 2.11 | |
| 2.03 | |
| 2.01 | |
| 1.92 | |
| 1.74 | |
| 1.76 | |
| 1.79 | |
| 1.69 | |
| 1.70 | |
| 1.68 | |
| 1.73 | |
| 1.69 | |
| 1.67 | |
| 1.68 | |
| 1.73 | |
| 1.72 | |
| 1.72 | |
| 1.69 | |
| 1.61 | |
| 1.59 | |
| 1.61 | |
| 1.60 | |
| 1.60 | |
| 1.62 | |
| 1.66 | |
| 1.60 | |
| 1.65 | |
| 1.60 | |
| 1.58 | |
| 1.50 | |
| 1.51 | |
| 1.57 | |
| 1.55 | |
| 1.48 | |
| 1.53 | |
| 1.59 | |
| 1.39 | |
| 1.31 | |
| 1.28 | |
| 1.29 | |
| 1.27 | |
| 1.38 | |
| 1.45 | |
| 1.44 | |
| 1.40 | |
| 1.42 | |
| 1.42 | |
| 1.46 | |
| 1.43 | |
| 1.42 | |
| 1.37 | |
| 1.39 | |
| 1.46 | |
| 1.47 | |
| 1.44 | |
| 1.44 | |
| 1.51 | |
| 1.44 | |
| 1.41 | |
| 1.42 | |
| 1.43 | |
| 1.39 | |
| 1.38 | |
| 1.36 | |
| 1.36 | |
| 1.34 | |
| 1.38 | |
| 1.31 | |
| 1.31 | |
| 1.25 | |
| 1.34 | |
| 1.34 | |
| 1.38 | |
| 1.38 | |
| 1.37 | |
| 1.39 | |
| 1.44 | |
| 1.40 | |
| 1.42 | |
| 1.43 | |
| 1.52 | |
| 1.52 | |
| 1.46 | |
| 1.51 | |
| 1.44 | |
| 1.59 | |
| 1.44 | |
| 1.45 | |
| 1.44 | |
| 1.40 | |
| 1.37 | |
| 1.41 | |
| 1.42 | |
| 1.39 | |
| 1.39 | |
| 1.39 | |
| 1.38 | |
| 1.36 | |
| 1.31 | |
| 1.11 | |
| 1.12 | |
| 1.09 | |
| 1.07 | |
| 1.06 | |
| 1.04 | |
| 1.07 | |
| 1.13 | |
| 1.12 | |
| 1.11 | |
| 1.11 | |
| 1.14 | |
| 1.14 | |
| 1.13 | |
| 1.09 | |
| 1.06 | |
| 1.08 | |
| 1.06 | |
| 1.07 | |
| 1.08 | |
| 1.06 | |
| 1.08 | |
| 1.06 | |
| 1.03 | |
| 1.01 | |
| 0.99 | |
| 0.96 | |
| 0.96 | |
| 0.95 | |
| 0.94 | |
| 0.96 | |
| 1.03 | |
| 1.02 | |
| 1.02 | |
| 1.02 | |
| 1.03 | |
| 0.99 | |
| 0.97 | |
| 0.97 | |
| 0.98 | |
| 0.97 | |
| 0.90 | |
| 0.89 | |
| 0.89 | |
| 0.87 | |
| 0.90 | |
| 0.93 | |
| 0.94 | |
| 0.92 | |
| 0.92 | |
| 0.93 | |
| 0.94 | |
| 0.95 | |
| 0.93 | |
| 0.97 | |
| 0.94 | |
| 0.96 | |
| 0.99 | |
| 0.97 | |
| 0.99 | |
| 0.99 | |
| 1.05 | |
| 1.23 | |
| 1.29 | |
| 1.26 | |
| 1.23 | |
| 1.23 | |
| 1.21 | |
| 1.24 | |
| 1.20 | |
| 1.25 | |
| 1.26 | |
| 1.27 | |
| 1.26 | |
| 1.23 | |
| 1.22 | |
| 1.21 | |
| 1.18 | |
| 1.19 | |
| 1.17 | |
| 1.16 | |
| 1.12 | |
| 1.10 | |
| 1.07 | |
| 1.05 | |
| 1.08 | |
| 1.06 | |
| 1.06 | |
| 1.07 | |
| 1.05 | |
| 1.12 | |
| 1.11 | |
| 1.09 | |
| 1.10 | |
| 1.10 | |
| 1.09 | |
| 1.07 | |
| 1.00 | |
| 0.98 | |
| 0.95 | |
| 0.94 | |
| 0.97 | |
| 0.96 | |
| 0.95 | |
| 0.96 | |
| 0.93 | |
| 0.92 | |
| 0.90 | |
| 0.93 | |
| 0.93 | |
| 0.94 | |
| 0.94 | |
| 0.94 | |
| 0.94 | |
| 0.93 | |
| 0.94 | |
| 0.94 | |
| 0.96 | |
| 0.96 |
Drugs
No drugs from this company are tracked yet.
FDA-approved applications
No Drugs@FDA application has a sponsor name that matches this company.
Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
| Metric | Reported value | Period | Filing |
|---|---|---|---|
| Revenue | 159,841,000 CAD | 1 Oct 2023 to 30 Sep 2024 FY2024 | 40-F for Revenue on sec.gov (opens in a new tab)Filed |
| Net income (loss) | −45,440,000 CAD | 1 Oct 2023 to 30 Sep 2024 FY2024 | 40-F for Net income (loss) on sec.gov (opens in a new tab)Filed |
| Research and development expense | 11,200,000 CAD | 1 Oct 2023 to 30 Sep 2024 FY2024 | 40-F for Research and development expense on sec.gov (opens in a new tab)Filed |
| Operating expenses | Not reported in XBRL filings since 2015 | ||
| Cash and cash equivalents | Not reported in XBRL filings since 2015 | ||
| Short-term investments and marketable securities | Not reported in XBRL filings since 2015 | ||
| Total liabilities | 101,871,000 CAD | At 30 Sep 2024 FY2024 | 40-F for Total liabilities on sec.gov (opens in a new tab)Filed |
| Stockholders' equity | 305,989,000 CAD | At 30 Sep 2024 FY2024 | 40-F for Stockholders' equity on sec.gov (opens in a new tab)Filed |
| Common shares outstanding (cover page) | 108,585,492 shares | At 30 Sep 2024 FY2024 | 40-F for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed |
History
| Period | Reported value | Filing |
|---|---|---|
| 1 Oct 2023 to 30 Sep 2024 FY2024 | 159,841,000 CAD | 40-F filed 18 Dec 2024 on sec.gov (opens in a new tab)Filed |
| 1 Sep 2022 to 30 Sep 2023 FY2024 | 161,639,000 CAD | 40-F filed 18 Dec 2024 on sec.gov (opens in a new tab)Filed |
| 1 Sep 2021 to 31 Aug 2022 FY2023 | 145,809,000 CAD | 40-F filed 19 Dec 2023 on sec.gov (opens in a new tab)Filed |
| 1 Sep 2020 to 31 Aug 2021 FY2022 | 79,163,000 CAD | 40-F filed 29 Nov 2022 on sec.gov (opens in a new tab)Filed |
| 1 Sep 2019 to 31 Aug 2020 FY2021 | 86,795,000 CAD | 40-F filed 23 Nov 2021 on sec.gov (opens in a new tab)Filed |
| 1 Sep 2018 to 31 Aug 2019 FY2020 | 80,413,000 CAD | 40-F filed 30 Nov 2020 on sec.gov (opens in a new tab)Filed |
| 1 Sep 2017 to 31 Aug 2018 FY2019 | 12,429,000 CAD | 40-F/A filed 27 Dec 2019 on sec.gov (opens in a new tab)Filed |
Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.
Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
No recent headlines mention this company.
Insider transactions
All rows for ORGANIGRAM GLOBAL INC. on Insider TradesLast 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).
- Buys code P
- None in this period
- Sells code S
- None in this period
- Other all other codes
- None in this period
Last transaction: none stored
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.